BRIEF RESEARCH REPORT
Published on 18 Jun 2025
An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer
doi 10.3389/fphar.2025.1605314
- 1,777 views